NEW YORK (
CHANGE IN RATINGS
( AONE) initiated at Barclays with an Equal Weight rating and $18 price target. A123 has the potential to emerge as a category leader in the li-ion battery market. 2010 and 2011 EPS estimates set at -$0.77 and -$0.34.
rated new Neutral at Goldman. $30 price target. Company is well run, but order activity has been weak in Government Systems.
rated new Neutral at MKM Partners. $570 price target. Stock is already pricing in accelerating global search advertising.
rated new Overweight at Morgan Stanley. IHS was initiated with an Overweight rating. $62 price target. Company can grow margins and is the most attractively valued stock in its group.
price target cut at Credit Suisse. NSPH price target trimmed by a dollar to $7. Estimates lowered through 2012. Maintain Outperform rating.
( PALM) downgraded at Morgan Stanley from Overweight to Equal-weight. Verizon has not backed the Palm launch with much marketing effort. Estimates also lowered.
STOCK COMMENTS / EPS CHANGES
estimates raised at FBR through 2011. Company has tight inventory controls and still generates strong comp sales. Outperform rating and $18 price target.
numbers boosted at FBR. Shares of CRM now seen reaching $75. Estimates also raised, as Service Cloud continues to gain traction.
estimates cut at UBS through 2011. Company is realizing better margins. Buy rating and $55 price target.
target, estimate raised at Barclays. DLTR price target jumped to $66 from $64 after 4Q10 numbers beat expectation. 2011 EPS estimate increased to $4.23 from $4.18. Maintain Overweight rating.
estimates, target upped at Goldman. DLTR estimates were increased through 2011. Company is realizing higher sales growth. Neutral rating and new $57 price target.
numbers increased at Goldman. ESRX estimates were boosted through 2012. Company has strong earnings momentum and improved visibility. Buy rating and new $115 price target.
target lowered at Morgan Stanley. ETR target was cut to $94. Vermont Yankee is facing re-licensing concerns. Overweight rating.
estimates, target increased at Goldman. Shares of GRMN now seen reaching $29. Estimates also raised, because of improving margins and lower taxes. Sell rating.
estimates cut at UBS. MRK estimates were lowered through 2011. Expect higher R&D spending and merger synergies to take longer to materialize. Buy rating and $45 price target.
estimates lowered at FBR through 2011. Company has healthy demand, but earnings growth may still settle down in the coming quarters. Outperform rating and $120 price target.
added to Conviction Buy List at Goldman. NKE was added to the Conviction Buy list. Company should soon return to better sales and earnings growth. Buy rating and $78 price target.
estimates boosted at Morgan Stanley through 2011. Expect higher Prevnar sales, following new FDA approval. Overweight rating and $22 price target.
estimates lowered at UBS through 2011. More Jackup rigs likely to hit the market and some concerns remain about deepwater. Buy rating and $115 price target.
estimates, target reduced at Goldman. Shares of SKS now seen reaching $6.80. Estimates also cut, because of higher operating and interest expenses. Neutral rating.
numbers boosted at Goldman. Shares of TJX now seen reaching $46. Estimates also raised, because of higher square footage growth and share buybacks. Buy rating.
This article was written by a staff member of TheStreet.com.